Last reviewed · How we verify

Ketamine + methadone — Competitive Intelligence Brief

Ketamine + methadone (Ketamine + methadone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist + synthetic opioid agonist combination. Area: Anesthesia, Pain Management, Psychiatry.

marketed NMDA receptor antagonist + synthetic opioid agonist combination NMDA receptor (ketamine); mu opioid receptor (methadone) Anesthesia, Pain Management, Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Ketamine + methadone (Ketamine + methadone) — Cedars-Sinai Medical Center. Ketamine and methadone together provide rapid-acting dissociative anesthesia combined with long-acting opioid analgesia and anti-inflammatory effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ketamine + methadone TARGET Ketamine + methadone Cedars-Sinai Medical Center marketed NMDA receptor antagonist + synthetic opioid agonist combination NMDA receptor (ketamine); mu opioid receptor (methadone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist + synthetic opioid agonist combination class)

  1. Cedars-Sinai Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamine + methadone — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-methadone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: